1
|
Li C, Szeto CC. Urinary podocyte markers in diabetic kidney disease. Kidney Res Clin Pract 2024; 43:274-286. [PMID: 38325865 PMCID: PMC11181047 DOI: 10.23876/j.krcp.23.109] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/01/2023] [Revised: 08/30/2023] [Accepted: 10/30/2023] [Indexed: 02/09/2024] Open
Abstract
Podocytes are involved in maintaining kidney function and are a major focus of research on diabetic kidney disease (DKD). Urinary biomarkers derived from podocyte fragments and molecules have been proposed for the diagnosis and monitoring of DKD. Various methods have been used to detect intact podocytes and podocyte-derived microvesicles in urine, including centrifugation, visualization, and molecular quantification. Quantification of podocyte-specific protein targets and messenger RNA levels can be performed by Western blotting or enzyme-linked immunosorbent assay and quantitative polymerase chain reaction, respectively. At present, many of these techniques are expensive and labor-intensive, all limiting their widespread use in routine clinical tests. While the potential of urinary podocyte markers for monitoring and risk stratification of DKD has been explored, systematic studies and external validation are lacking in the current literature. Standardization and automation of laboratory methods should be a priority for future research, and the added value of these methods to routine clinical tests should be defined.
Collapse
Affiliation(s)
- Chuanlei Li
- Carol & Richard Yu Peritoneal Dialysis Research Centre, Department of Medicine and Therapeutics, Prince of Wales Hospital, The Chinese University of Hong Kong, Shatin, Hong Kong, China
- Li Ka Shing Institute of Health Sciences, Faculty of Medicine, The Chinese University of Hong Kong, Shatin, Hong Kong, China
| | - Cheuk-Chun Szeto
- Carol & Richard Yu Peritoneal Dialysis Research Centre, Department of Medicine and Therapeutics, Prince of Wales Hospital, The Chinese University of Hong Kong, Shatin, Hong Kong, China
- Li Ka Shing Institute of Health Sciences, Faculty of Medicine, The Chinese University of Hong Kong, Shatin, Hong Kong, China
| |
Collapse
|
2
|
Requena T, Keder A, zur Lage P, Albert JT, Jarman AP. A Drosophila model for Meniere's disease: Dystrobrevin is required for support cell function in hearing and proprioception. Front Cell Dev Biol 2022; 10:1015651. [PMID: 36438562 PMCID: PMC9688402 DOI: 10.3389/fcell.2022.1015651] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/09/2022] [Accepted: 10/27/2022] [Indexed: 08/04/2023] Open
Abstract
Meniere's disease (MD) is an inner ear disorder characterised by recurrent vertigo attacks associated with sensorineural hearing loss and tinnitus. Evidence from epidemiology and Whole Exome Sequencing (WES) suggests a genetic susceptibility involving multiple genes, including α-Dystrobrevin (DTNA). Here we investigate a Drosophila model. We show that mutation, or knockdown, of the DTNA orthologue in Drosophila, Dystrobrevin (Dyb), results in defective proprioception and impaired function of Johnston's Organ (JO), the fly's equivalent of the inner ear. Dyb and another component of the dystrophin-glycoprotein complex (DGC), Dystrophin (Dys), are expressed in support cells within JO. Their specific locations suggest that they form part of support cell contacts, thereby helping to maintain the integrity of the hemolymph-neuron diffusion barrier, which is equivalent to a blood-brain barrier. These results have important implications for the human condition, and notably, we note that DTNA is expressed in equivalent cells of the mammalian inner ear.
Collapse
Affiliation(s)
- T. Requena
- Biomedical Sciences: Centre for Discovery Brain Sciences, Edinburgh Medical School, University of Edinburgh, Edinburgh, United Kingdom
- Division of Functional Genetics and Development, The Royal Dick School of Veterinary Sciences, The Roslin Institute, The University of Edinburgh, Edinburgh, United Kingdom
| | - A. Keder
- Ear Institute, University College London, London, United Kingdom
| | - P. zur Lage
- Biomedical Sciences: Centre for Discovery Brain Sciences, Edinburgh Medical School, University of Edinburgh, Edinburgh, United Kingdom
| | - J. T. Albert
- Ear Institute, University College London, London, United Kingdom
| | - A. P. Jarman
- Biomedical Sciences: Centre for Discovery Brain Sciences, Edinburgh Medical School, University of Edinburgh, Edinburgh, United Kingdom
| |
Collapse
|
3
|
Urinary podocyte markers in kidney diseases. Clin Chim Acta 2021; 523:315-324. [PMID: 34666027 DOI: 10.1016/j.cca.2021.10.017] [Citation(s) in RCA: 12] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/18/2021] [Revised: 09/17/2021] [Accepted: 10/13/2021] [Indexed: 01/19/2023]
Abstract
Podocytes play an important role in the maintenance of kidney function, and they are the primary focus of many kidney diseases. Podocyte injury results in the shedding of podocyte-derived cellular fragments and podocyte-specific molecular targets into the urine, which may serve as biomarkers of kidney diseases. Intact podocytes, either viable or dead, and podocyte-derived microvesicles could be quantified in the urine by various centrifugation, visualization and culture methods. Podocyte-specific protein targets from the nucleus, cytoplasm, slit-diaphragm, glomerular capillary basement membrane, and cytoskeleton, as well as their corresponding messenger RNA (mRNA), in the urine could be quantified by western blotting, ELISA, or quantitative polymerase chain reaction. Although some of these techniques may be expensive or labor-intensive at present, they may become widely available in the future because of the improvement in technology and automation. The application of urinary podocyte markers for the diagnosis and monitoring of various kidney diseases have been explored but the published data in this area are not sufficiently systematic and lack external validation. Further research should focus on standardizing, comparing, and automizing laboratory methods, as well as defining their added value to the routine clinical tests.
Collapse
|
4
|
Marshall CB. Rethinking glomerular basement membrane thickening in diabetic nephropathy: adaptive or pathogenic? Am J Physiol Renal Physiol 2016; 311:F831-F843. [PMID: 27582102 DOI: 10.1152/ajprenal.00313.2016] [Citation(s) in RCA: 72] [Impact Index Per Article: 9.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/27/2016] [Accepted: 08/21/2016] [Indexed: 12/12/2022] Open
Abstract
Diabetic nephropathy (DN) is the leading cause of chronic kidney disease in the United States and is a major cause of cardiovascular disease and death. DN develops insidiously over a span of years before clinical manifestations, including microalbuminuria and declining glomerular filtration rate (GFR), are evident. During the clinically silent period, structural lesions develop, including glomerular basement membrane (GBM) thickening, mesangial expansion, and glomerulosclerosis. Once microalbuminuria is clinically apparent, structural lesions are often considerably advanced, and GFR decline may then proceed rapidly toward end-stage kidney disease. Given the current lack of sensitive biomarkers for detecting early DN, a shift in focus toward examining the cellular and molecular basis for the earliest structural change in DN, i.e., GBM thickening, may be warranted. Observed within one to two years following the onset of diabetes, GBM thickening precedes clinically evident albuminuria. In the mature glomerulus, the podocyte is likely key in modifying the GBM, synthesizing and assembling matrix components, both in physiological and pathological states. Podocytes also secrete matrix metalloproteinases, crucial mediators in extracellular matrix turnover. Studies have shown that the critical podocyte-GBM interface is disrupted in the diabetic milieu. Just as healthy podocytes are essential for maintaining the normal GBM structure and function, injured podocytes likely have a fundamental role in upsetting the balance between the GBM's synthetic and degradative pathways. This article will explore the biological significance of GBM thickening in DN by reviewing what is known about the GBM's formation, its maintenance during health, and its disruption in DN.
Collapse
Affiliation(s)
- Caroline B Marshall
- Division of Nephrology, Department of Medicine, University of Alabama at Birmingham, Birmingham, Alabama; and Department of Veterans Affairs Medical Center, Birmingham, Alabama
| |
Collapse
|
5
|
Smeets B, Stucker F, Wetzels J, Brocheriou I, Ronco P, Gröne HJ, D'Agati V, Fogo AB, van Kuppevelt TH, Fischer HP, Boor P, Floege J, Ostendorf T, Moeller MJ. Detection of activated parietal epithelial cells on the glomerular tuft distinguishes early focal segmental glomerulosclerosis from minimal change disease. THE AMERICAN JOURNAL OF PATHOLOGY 2014; 184:3239-48. [PMID: 25307344 DOI: 10.1016/j.ajpath.2014.08.007] [Citation(s) in RCA: 66] [Impact Index Per Article: 6.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Subscribe] [Scholar Register] [Received: 02/28/2014] [Revised: 08/11/2014] [Accepted: 08/22/2014] [Indexed: 12/26/2022]
Abstract
In rodents, parietal epithelial cells (PECs) migrating onto the glomerular tuft participate in the formation of focal segmental glomerulosclerosis (FSGS) lesions. We investigated whether immunohistologic detection of PEC markers in the initial biopsies of human patients with first manifestation of idiopathic nephrotic syndrome with no immune complexes can improve the sensitivity to detect sclerotic lesions compared with standard methods. Ninety-five renal biopsies were stained for claudin-1 (PEC marker), CD44 (activated PECs), and LKIV69 (PEC matrix); 38 had been diagnosed as early primary FSGS and 57 as minimal change disease. PEC markers were detected on the tuft in 87% of the biopsies of patients diagnosed as primary FSGS. PEC markers were detected in FSGS lesions from the earliest stages of disease. In minimal change disease, no PEC activation was observed by immunohistology. However, in 25% of biopsies originally diagnosed as minimal change disease the presence of small lesions indicative of a sclerosing process were detected, which were undetectable on standard periodic acid-Schiff staining, even though only a single histologic section for each PEC marker was evaluated. Staining for LKIV69 detected lesions with the highest sensitivity. Two novel PEC markers A-kinase anchor protein 12 and annexin A3 exhibited similar sensitivity. In summary, detection of PECs on the glomerular tuft by immunostaining improves the differentiation between minimal change disease and primary FSGS and may serve to guide clinical decision making.
Collapse
Affiliation(s)
- Bart Smeets
- Division of Nephrology and Clinical Immunology, Department of Internal Medicine II, RWTH Aachen University Hospital, Aachen, Germany
| | - Fabien Stucker
- Department of Pathology, INSERM U702, Hôpital Tenon, Paris, France; Nephrology Service, University Hospitals of Geneva (HUG), Geneva, Switzerland
| | - Jack Wetzels
- Department of Nephrology, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands
| | | | - Pierre Ronco
- Department of Pathology, INSERM U702, Hôpital Tenon, Paris, France
| | - Hermann-Josef Gröne
- Department of Cellular and Molecular Pathology, German Cancer Research Center, Heidelberg, Germany
| | - Vivette D'Agati
- Department of Pathology, Columbia University, College of Physicians and Surgeons, New York, New York
| | - Agnes B Fogo
- Department of Pathology, Microbiology and Immunology, Vanderbilt University Medical Center, Nashville, Tennessee
| | - Toin H van Kuppevelt
- Department of Biochemistry, NCMLS, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands
| | - Hans-Peter Fischer
- Q1 platform of the TRR57, Institute for Pathology, Sigmund-Freud-Straße 25, Bonn, Germany
| | - Peter Boor
- Q1 platform of the TRR57, Institute for Pathology, RWTH Aachen University Hospital, Aachen, Germany
| | - Jürgen Floege
- Division of Nephrology and Clinical Immunology, Department of Internal Medicine II, RWTH Aachen University Hospital, Aachen, Germany
| | - Tammo Ostendorf
- Division of Nephrology and Clinical Immunology, Department of Internal Medicine II, RWTH Aachen University Hospital, Aachen, Germany
| | - Marcus J Moeller
- Division of Nephrology and Clinical Immunology, Department of Internal Medicine II, RWTH Aachen University Hospital, Aachen, Germany.
| |
Collapse
|
6
|
A compendium of urinary biomarkers indicative of glomerular podocytopathy. PATHOLOGY RESEARCH INTERNATIONAL 2013; 2013:782395. [PMID: 24327929 PMCID: PMC3845336 DOI: 10.1155/2013/782395] [Citation(s) in RCA: 25] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 07/22/2013] [Accepted: 09/10/2013] [Indexed: 12/18/2022]
Abstract
It is well known that glomerular podocyte injury and loss are present in numerous nephropathies and that the pathophysiologic consecution of disease hinges upon the fate of the podocyte. While multiple factors play a hand in glomerulopathy progression, basic logic lends that if one monitors the podocyte's status, that may reflect the status of disease. Recent investigations have focused on what one can elucidate from the noninvasive collection of urine, and have proven that certain, specific biomarkers of podocytes can be readily identified via varying techniques. This paper has brought together all described urinary biomarkers of podocyte injury and is made to provide a concise summary of their utility and testing in laboratory and clinical theatres. While promising in the potential that they hold as tools for clinicians and investigators, the described biomarkers require further comprehensive vetting in the form of larger clinical trials and studies that would give their value true weight. These urinary biomarkers are put forth as novel indicators of glomerular disease presence, disease progression, and therapeutic efficacy that in some cases may be more advantageous than the established parameters/measures currently used in practice.
Collapse
|
7
|
Abstract
This article summarizes the basic cellular and extracellular events in the development of the glomerulus and assembly of the glomerular basement membrane (GBM), paying special attention to laminin (LM) and type IV collagen. Cellular receptors for GBM proteins, including the integrins, dystroglycan, and discoidin domain receptor 1 also are discussed. Evidence is reviewed showing that the laminin isoform present in the earliest GBM, LM-111, and final isoform found in the mature GBM, LM-521, are each derived from both endothelial cells and podocytes. Although the early collagen α1α2α1(IV) similarly derives from endothelial cells and podocytes, collagen α3α4α5(IV) found in fully mature GBM is a product solely of podocytes. Genetic diseases affecting laminin and type IV collagen synthesis also are presented, with an emphasis on mutations to LAMB2 (Pierson syndrome) and COL4A3, COL4A4, and COL4A5 (Alport syndrome), and their experimental mouse models. Stress is placed on the assembly of a compositionally correct GBM for the acquisition and maintenance of glomerular barrier properties.
Collapse
Affiliation(s)
- Dale R Abrahamson
- Department of Anatomy and Cell Biology, University of Kansas Medical Center, Kansas City, KS 66160, USA.
| |
Collapse
|
8
|
Borza CM, Pozzi A. The role of cell-extracellular matrix interactions in glomerular injury. Exp Cell Res 2012; 318:1001-10. [PMID: 22417893 DOI: 10.1016/j.yexcr.2012.02.033] [Citation(s) in RCA: 20] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/03/2012] [Accepted: 02/24/2012] [Indexed: 01/09/2023]
Abstract
Glomerulosclerosis is characterized by excessive deposition of extracellular matrix within the glomeruli of the kidney, glomerular cell death, and subsequent loss of functional glomeruli. While in physiological situations the levels of extracellular matrix components are kept constant by a tight balance between formation and degradation, in the case of injury that results in fibrosis there is increased matrix deposition relative to its breakdown. Multiple factors control matrix synthesis and degradation, thus contributing to the development of glomerulosclerosis. This review focuses primarily on the role of cell-matrix interactions, which play a critical role in governing glomerular cell cues in both healthy and diseased kidneys. Cell-extracellular matrix interactions are made possible by various cellular receptors including integrins, discoidin domain receptors, and dystroglycan. Upon binding to a selective extracellular matrix protein, these receptors activate intracellular signaling pathways that can either downregulate or upregulate matrix synthesis and deposition. This, together with the observation that changes in the expression levels of matrix receptors have been documented in glomerular disease, clearly emphasizes the contribution of cell-matrix interactions in glomerular injury. Understanding the molecular mechanisms whereby extracellular matrix receptors regulate matrix homeostasis in the course of glomerular injury is therefore critical for devising more effective therapies to treat and ideally prevent glomerulosclerosis.
Collapse
Affiliation(s)
- Corina M Borza
- Department of Medicine, Division of Nephrology, Vanderbilt University, Nashville, TN 37232, USA.
| | | |
Collapse
|
9
|
Kakani S, Yardeni T, Poling J, Ciccone C, Niethamer T, Klootwijk ED, Manoli I, Darvish D, Hoogstraten-Miller S, Zerfas P, Tian E, Ten Hagen KG, Kopp JB, Gahl WA, Huizing M. The Gne M712T mouse as a model for human glomerulopathy. THE AMERICAN JOURNAL OF PATHOLOGY 2012; 180:1431-40. [PMID: 22322304 DOI: 10.1016/j.ajpath.2011.12.023] [Citation(s) in RCA: 20] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 05/03/2011] [Revised: 10/13/2011] [Accepted: 12/09/2011] [Indexed: 12/17/2022]
Abstract
Pathological glomerular hyposialylation has been implicated in certain unexplained glomerulopathies, including minimal change nephrosis, membranous glomerulonephritis, and IgA nephropathy. We studied our previously established mouse model carrying a homozygous mutation in the key enzyme of sialic acid biosynthesis, N-acetylglucosamine 2-epimerase/N-acetylmannosamine kinase. Mutant mice died before postnatal day 3 (P3) from severe glomerulopathy with podocyte effacement and segmental glomerular basement membrane splitting due to hyposialylation. Administration of the sialic acid precursor N-acetylmannosamine (ManNAc) led to improved sialylation and survival of mutant pups beyond P3. We determined the onset of the glomerulopathy in the embryonic stage. A lectin panel, distinguishing normally sialylated from hyposialylated glycans, used WGA, SNA, PNA, Jacalin, HPA, and VVA, indicating glomerular hyposialylation of predominantly O-linked glycoproteins in mutant mice. The glomerular glycoproteins nephrin and podocalyxin were hyposialylated in this unique murine model. ManNAc treatment appeared to ameliorate the hyposialylation status of mutant mice, indicated by a lectin histochemistry pattern similar to that of wild-type mice, with improved sialylation of both nephrin and podocalyxin, as well as reduced albuminuria compared with untreated mutant mice. These findings suggest application of our lectin panel for categorizing human kidney specimens based on glomerular sialylation status. Moreover, the partial restoration of glomerular architecture in ManNAc-treated mice highlights ManNAc as a potential treatment for humans affected with disorders of glomerular hyposialylation.
Collapse
Affiliation(s)
- Sravan Kakani
- Medical Genetics Branch, National Human Genome Research Institute, National Institutes of Health, Bethesda, Maryland 20892-1851, USA
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
10
|
Vogtlander NPJ, van der Vlag J, Bakker MAH, Dijkman HB, Wevers RA, Campbell KP, Wetzels JFM, Berden JHM. Expression of sialidase and dystroglycan in human glomerular diseases. Nephrol Dial Transplant 2009; 25:478-84. [DOI: 10.1093/ndt/gfp465] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
11
|
Vogtländer NPJ, Visch HJ, Bakker MAH, Berden JHM, van der Vlag J. Ligation of alpha-dystroglycan on podocytes induces intracellular signaling: a new mechanism for podocyte effacement? PLoS One 2009; 4:e5979. [PMID: 19543532 PMCID: PMC2695560 DOI: 10.1371/journal.pone.0005979] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/11/2008] [Accepted: 05/15/2009] [Indexed: 12/20/2022] Open
Abstract
Background α-Dystroglycan is a negatively charged glycoprotein that covers the apical and basolateral membrane of the podocyte. Its transmembrane binding to the cytoskeleton is regulated via tyrosine phosphorylation (pY892) of β-dystroglycan. At the basolateral side α-dystroglycan binds the glomerular basement membrane. At the apical membrane, it plays a role in the maintenance of the filtration slit. In this study, we evaluated whether ligation of α-dystroglycan with specific antibodies or natural ligands induces intracellular signaling, and whether there is an effect on podocyte architecture. Methodology/Principal Findings Conditionally immortalized podocytes were exposed in vitro to antibodies to α-dystroglycan, and to fibronectin, biglycan, laminin and agrin. Intracellular calcium fluxes, phosphorylation of β-dystroglycan and podocyte architecture were studied. Antibodies to α-dystroglycan could specifically induce calcium signaling. Fibronectin also induced calcium signaling, and led to dephosphorylation of pY892 in β-dystroglycan. Ligation of α-dystroglycan resulted in an altered actin architecture, a decreased number of podocyte pedicles and a more flattened appearance of the podocyte. Conclusions/Significance We conclude that ligation of α-dystroglycan on podocytes induces intracellular calcium signaling, which leads to an altered cytoskeleton architecture akin to the situation of foot process effacement. In particular the ability of fibronectin to induce intracellular signaling events is of interest, since the expression and excretion of this protein is upregulated in several proteinuric diseases. Therefore, fibronectin-induced signaling via dystroglycan may be a novel mechanism for foot process effacement in proteinuric diseases.
Collapse
Affiliation(s)
- Nils P. J. Vogtländer
- Nephrology Research Laboratory, Nijmegen Centre for Molecular Life Sciences, Division of Nephrology, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands
| | - Henk Jan Visch
- Department of Biochemistry, Nijmegen Centre for Molecular Life Sciences, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands
| | - Marinka A. H. Bakker
- Nephrology Research Laboratory, Nijmegen Centre for Molecular Life Sciences, Division of Nephrology, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands
| | - Jo H. M. Berden
- Nephrology Research Laboratory, Nijmegen Centre for Molecular Life Sciences, Division of Nephrology, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands
| | - Johan van der Vlag
- Nephrology Research Laboratory, Nijmegen Centre for Molecular Life Sciences, Division of Nephrology, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands
- * E-mail:
| |
Collapse
|
12
|
Ishiyama A, Mowry SE, Lopez IA, Ishiyama G. Immunohistochemical distribution of basement membrane proteins in the human inner ear from older subjects. Hear Res 2009; 254:1-14. [PMID: 19348877 DOI: 10.1016/j.heares.2009.03.014] [Citation(s) in RCA: 26] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/12/2008] [Revised: 03/02/2009] [Accepted: 03/27/2009] [Indexed: 11/27/2022]
Abstract
The immunolocalization of several basement membrane (BM) proteins was investigated in vestibular endorgans microdissected from temporal bones obtained from subjects with a documented normal auditory and vestibular function (n=5, average age=88 years old). Fluorescent immunostaining using antibodies directed at collagen IV alpha 2, nidogen-1, laminin-beta2, alpha-dystroglycan, and tenascin-C was applied to cryosections from human cochlea, cristae ampullares, utricular and saccular maculae. Collagen IV alpha 2, nidogen-1, and laminin-beta2 localized to all subepithelial cochlear BMs, Reissner's membrane, strial and spiral ligamental perineural and perivascular BMs, and the spiral limbus. Tenascin-C localized to the basilar membrane and the osseous spiral lamina. alpha-Dystroglycan localized to most cochlear BMs except those in the spiral ligament, basilar membrane and spiral limbus. Collagen IV, nidogen-1, and laminin-beta2 localized to the subepithelial BMs of the maculae and cristae ampullares, and the perineural and perivascular BMs within the underlying stroma. The BM underlying the transitional and dark cell region of the cristae ampullares also expressed collagen IV, nidogen-1, and laminin-beta2. Tenascin-C localized to the subepithelial BMs of the utricular maculae and cristae ampullares, and to calyx-like profiles throughout the vestibular epithelium, but not to the perineural and perivascular BMs. alpha-Dystroglycan colocalized with aquaporin-4 in the basal vestibular supporting cell, and was also expressed in the subepithelial BMs, as well as perivascular and perineural BMs. This study provides the first comprehensive immunolocalization of these ECM proteins in the human inner ear. The validity of the rodent models for inner ear disorders secondary to BM pathologies was confirmed as there is a high degree of conservation of expression of these proteins in the human inner ear. This information is critical to begin to unravel the role that BMs may play in human inner ear physiology and audiovestibular pathologies.
Collapse
Affiliation(s)
- Akira Ishiyama
- Department of Surgery, Division of Head and Neck, David Geffen School of Medicine, UCLA, Los Angeles, CA 90095-1769, USA
| | | | | | | |
Collapse
|
13
|
Galeano B, Klootwijk R, Manoli I, Sun M, Ciccone C, Darvish D, Starost MF, Zerfas PM, Hoffmann VJ, Hoogstraten-Miller S, Krasnewich DM, Gahl WA, Huizing M. Mutation in the key enzyme of sialic acid biosynthesis causes severe glomerular proteinuria and is rescued by N-acetylmannosamine. J Clin Invest 2007; 117:1585-94. [PMID: 17549255 PMCID: PMC1878529 DOI: 10.1172/jci30954] [Citation(s) in RCA: 157] [Impact Index Per Article: 9.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/14/2006] [Accepted: 03/27/2007] [Indexed: 12/29/2022] Open
Abstract
Mutations in the key enzyme of sialic acid biosynthesis, uridine diphospho-N-acetylglucosamine 2-epimerase/N-acetylmannosamine (ManNAc) kinase (GNE/MNK), result in hereditary inclusion body myopathy (HIBM), an adult-onset, progressive neuromuscular disorder. We created knockin mice harboring the M712T Gne/Mnk mutation. Homozygous mutant (Gne(M712T/M712T)) mice did not survive beyond P3. At P2, significantly decreased Gne-epimerase activity was observed in Gne(M712T/M712T) muscle, but no myopathic features were apparent. Rather, homozygous mutant mice had glomerular hematuria, proteinuria, and podocytopathy. Renal findings included segmental splitting of the glomerular basement membrane, effacement of podocyte foot processes, and reduced sialylation of the major podocyte sialoprotein, podocalyxin. ManNAc administration yielded survival beyond P3 in 43% of the Gne(M712T/M712T) pups. Survivors exhibited improved renal histology, increased sialylation of podocalyxin, and increased Gne/Mnk protein expression and Gne-epimerase activities. These findings establish this Gne(M712T/M712T) knockin mouse as what we believe to be the first genetic model of podocyte injury and segmental glomerular basement membrane splitting due to hyposialylation. The results also support evaluation of ManNAc as a treatment not only for HIBM but also for renal disorders involving proteinuria and hematuria due to podocytopathy and/or segmental splitting of the glomerular basement membrane.
Collapse
Affiliation(s)
- Belinda Galeano
- Medical Genetics Branch, National Human Genome Research Institute, NIH, Bethesda, Maryland, USA.
Howard Hughes Medical Institute/NIH Research Scholars Program, Bethesda, Maryland, USA.
HIBM Research Group, Encino, California, USA.
Division of Veterinary Resources,
Office of Laboratory Animal Medicine, National Human Genome Research Institute, and
Office of Rare Diseases, Office of the Director, NIH, Bethesda, Maryland, USA
| | - Riko Klootwijk
- Medical Genetics Branch, National Human Genome Research Institute, NIH, Bethesda, Maryland, USA.
Howard Hughes Medical Institute/NIH Research Scholars Program, Bethesda, Maryland, USA.
HIBM Research Group, Encino, California, USA.
Division of Veterinary Resources,
Office of Laboratory Animal Medicine, National Human Genome Research Institute, and
Office of Rare Diseases, Office of the Director, NIH, Bethesda, Maryland, USA
| | - Irini Manoli
- Medical Genetics Branch, National Human Genome Research Institute, NIH, Bethesda, Maryland, USA.
Howard Hughes Medical Institute/NIH Research Scholars Program, Bethesda, Maryland, USA.
HIBM Research Group, Encino, California, USA.
Division of Veterinary Resources,
Office of Laboratory Animal Medicine, National Human Genome Research Institute, and
Office of Rare Diseases, Office of the Director, NIH, Bethesda, Maryland, USA
| | - MaoSen Sun
- Medical Genetics Branch, National Human Genome Research Institute, NIH, Bethesda, Maryland, USA.
Howard Hughes Medical Institute/NIH Research Scholars Program, Bethesda, Maryland, USA.
HIBM Research Group, Encino, California, USA.
Division of Veterinary Resources,
Office of Laboratory Animal Medicine, National Human Genome Research Institute, and
Office of Rare Diseases, Office of the Director, NIH, Bethesda, Maryland, USA
| | - Carla Ciccone
- Medical Genetics Branch, National Human Genome Research Institute, NIH, Bethesda, Maryland, USA.
Howard Hughes Medical Institute/NIH Research Scholars Program, Bethesda, Maryland, USA.
HIBM Research Group, Encino, California, USA.
Division of Veterinary Resources,
Office of Laboratory Animal Medicine, National Human Genome Research Institute, and
Office of Rare Diseases, Office of the Director, NIH, Bethesda, Maryland, USA
| | - Daniel Darvish
- Medical Genetics Branch, National Human Genome Research Institute, NIH, Bethesda, Maryland, USA.
Howard Hughes Medical Institute/NIH Research Scholars Program, Bethesda, Maryland, USA.
HIBM Research Group, Encino, California, USA.
Division of Veterinary Resources,
Office of Laboratory Animal Medicine, National Human Genome Research Institute, and
Office of Rare Diseases, Office of the Director, NIH, Bethesda, Maryland, USA
| | - Matthew F. Starost
- Medical Genetics Branch, National Human Genome Research Institute, NIH, Bethesda, Maryland, USA.
Howard Hughes Medical Institute/NIH Research Scholars Program, Bethesda, Maryland, USA.
HIBM Research Group, Encino, California, USA.
Division of Veterinary Resources,
Office of Laboratory Animal Medicine, National Human Genome Research Institute, and
Office of Rare Diseases, Office of the Director, NIH, Bethesda, Maryland, USA
| | - Patricia M. Zerfas
- Medical Genetics Branch, National Human Genome Research Institute, NIH, Bethesda, Maryland, USA.
Howard Hughes Medical Institute/NIH Research Scholars Program, Bethesda, Maryland, USA.
HIBM Research Group, Encino, California, USA.
Division of Veterinary Resources,
Office of Laboratory Animal Medicine, National Human Genome Research Institute, and
Office of Rare Diseases, Office of the Director, NIH, Bethesda, Maryland, USA
| | - Victoria J. Hoffmann
- Medical Genetics Branch, National Human Genome Research Institute, NIH, Bethesda, Maryland, USA.
Howard Hughes Medical Institute/NIH Research Scholars Program, Bethesda, Maryland, USA.
HIBM Research Group, Encino, California, USA.
Division of Veterinary Resources,
Office of Laboratory Animal Medicine, National Human Genome Research Institute, and
Office of Rare Diseases, Office of the Director, NIH, Bethesda, Maryland, USA
| | - Shelley Hoogstraten-Miller
- Medical Genetics Branch, National Human Genome Research Institute, NIH, Bethesda, Maryland, USA.
Howard Hughes Medical Institute/NIH Research Scholars Program, Bethesda, Maryland, USA.
HIBM Research Group, Encino, California, USA.
Division of Veterinary Resources,
Office of Laboratory Animal Medicine, National Human Genome Research Institute, and
Office of Rare Diseases, Office of the Director, NIH, Bethesda, Maryland, USA
| | - Donna M. Krasnewich
- Medical Genetics Branch, National Human Genome Research Institute, NIH, Bethesda, Maryland, USA.
Howard Hughes Medical Institute/NIH Research Scholars Program, Bethesda, Maryland, USA.
HIBM Research Group, Encino, California, USA.
Division of Veterinary Resources,
Office of Laboratory Animal Medicine, National Human Genome Research Institute, and
Office of Rare Diseases, Office of the Director, NIH, Bethesda, Maryland, USA
| | - William A. Gahl
- Medical Genetics Branch, National Human Genome Research Institute, NIH, Bethesda, Maryland, USA.
Howard Hughes Medical Institute/NIH Research Scholars Program, Bethesda, Maryland, USA.
HIBM Research Group, Encino, California, USA.
Division of Veterinary Resources,
Office of Laboratory Animal Medicine, National Human Genome Research Institute, and
Office of Rare Diseases, Office of the Director, NIH, Bethesda, Maryland, USA
| | - Marjan Huizing
- Medical Genetics Branch, National Human Genome Research Institute, NIH, Bethesda, Maryland, USA.
Howard Hughes Medical Institute/NIH Research Scholars Program, Bethesda, Maryland, USA.
HIBM Research Group, Encino, California, USA.
Division of Veterinary Resources,
Office of Laboratory Animal Medicine, National Human Genome Research Institute, and
Office of Rare Diseases, Office of the Director, NIH, Bethesda, Maryland, USA
| |
Collapse
|
14
|
Vogtländer NPJ, Tamboer WPM, Bakker MAH, Campbell KP, van der Vlag J, Berden JHM. Reactive oxygen species deglycosilate glomerular alpha-dystroglycan. Kidney Int 2006; 69:1526-34. [PMID: 16672922 DOI: 10.1038/sj.ki.5000138] [Citation(s) in RCA: 22] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/26/2022]
Abstract
In the kidney, dystroglycan (DG) has been shown to cover the basolateral and apical membranes of the podocyte. alpha-DG is heavily glycosilated, which is important for its binding to laminin and agrin in the glomerular basement membrane. Furthermore, alpha-DG is negatively charged, which maintains the filtration slit open. Reactive oxygen species (ROS) are known to degrade and depolymerize carbohydrates, and to play a role in several glomerular diseases. Therefore, we evaluated the effect of ROS on the glycosilation of glomerular alpha-DG. By using specific antibodies directed against the core protein or glyco-epitopes of alpha-DG, this was studied in a solid-phase assay, in situ on kidney sections, and in vivo in adriamycin nephropathy. A ligand overlay assay was used to study binding of alpha-DG to its ligands. Exposure to ROS leads to a loss of carbohydrate epitopes on alpha-DG both in vitro and on kidney sections. In the in vitro assays, a decreased binding of deglycosilated alpha-DG to laminin and agrin was found. In adriamycin nephropathy, where radicals play a role, we observed a loss of alpha-DG carbohydrate epitopes. We conclude that deglycosilation of glomerular alpha-DG by ROS leads to disruption of the agrin-DG complex, which in vivo may lead to the detachment of podocytes. Furthermore, loss of negative charge in the filtration slit may lead to foot process effacement of podocytes.
Collapse
Affiliation(s)
- N P J Vogtländer
- Division of Nephrology, Nijmegen Centre for Molecular Life Sciences, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands
| | | | | | | | | | | |
Collapse
|